Protective effects of telmisartan on ischemia/reperfusion injury of rat ovary: biochemical and histopathologic evaluation.
OBJECTIVE
To evaluate the effects of telmisartan as an antioxidant and for its tissue protective properties and to study the biochemical and histopathologic changes in experimental ischemia and ischemia/reperfusion injuries in rat ovaries.


METHODS
Experimental study.


METHODS
Experimental surgery laboratory in a university department.


METHODS
Forty-eight female adult rats.


METHODS
I: sham operation; II: bilateral ovarian ischemia; III: 3 h ischemia + 3 h reperfusion. IV and V: Rats were administered 10 and 20 mg/kg doses of telmisartan, respectively, before 0.5 h of ischemia, and then ovarian ischemia was applied; after 3 h of ischemia, the ovaries were removed. VI and VII: 3 h ovarian ischemia was applied; 2.5 h after the induction of ischemia, rats were administered the same doses of telmisartan; at the end of 3 h of ischemia, the ovaries were removed and a 3 h reperfusion followed.


METHODS
Superoxide dismutase, inducible nitric oxide synthase, and myeloperoxidase activity in rat ovarian tissue; and histopathologic changes in the ovarian tissue of the rats.


RESULTS
Ischemia and ischemia-reperfusion increased the inducible nitric oxide synthase and myeloperoxidase activity while decreasing the super oxide dismutase activity significantly in comparison with the sham group. Before ischemia and ischemia/reperfusion, telmisartan reversed the trend in inducible nitric oxide synthase activities and the level of myeloperoxidase.


CONCLUSIONS
telmisartan is effective in reversing tissue damage induced by ischemia/reperfusion in ovaries.
Kumtepe
Yakup
Y
Department of Obstetrics and Gynecology, Ataturk University School of Medicine, Terminal cad no. 14/2, 25200 Erzurum, Turkey. ykumtepe@hotmail.com
Odabasoglu
Fehmi
F
Karaca
Mehmet
M
Polat
Beyzagul
B
Halici
Mesut Bünyamin
MB
Keles
Osman Nuri
ON
Altunkaynak
Zuhal
Z
Gocer
Fatma
F
D000818:Animals; D000975:Antioxidants / Q000378:metabolism / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005260:Female; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D010053:Ovary / Q000098:blood supply* / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology; D009195:Peroxidase / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology / Q000517:prevention & control*; D013482:Superoxide Dismutase / Q000378:metabolism; D000077333:Telmisartan
D000975:Antioxidants; D001562:Benzimidazoles; D001565:Benzoates; D009195:Peroxidase; D052247:Nitric Oxide Synthase Type II; D013482:Superoxide Dismutase; D000077333:Telmisartan